Management has presented these non-GAAP financial measures because it believes they may be useful to investors for various reasons, but these measures should not be viewed as a substitute for or superior to the company's financial results prepared in accordance with GAAP. Please see the company's press release discussing its financial results for the fourth quarter 2025 for more information, including the description of how the company calculates non-GAAP income and loss, non-GAAP earnings and loss per shar ...

Key Takeaways LNG is set to report Q4 2025 earnings on Feb. 26, with EPS estimated at $3.83 per share.Revenues are expected to rise 16.66% year over year, driven by higher LNG sales and demand.Cheniere Energy has a 0.48% Earnings ESP and beat estimates in three of the last four quarters.Cheniere Energy, Inc. (LNG) is set to release fourth-quarter 2025 results on Feb. 26. The Zacks Consensus Estimate for earnings is pegged at $3.83 per share on revenues of $5.17 billion.Let us delve into the factors that are ...

Group 1: Stock Performance - Several healthcare and biotech stocks experienced significant gains in after-hours trading, with movements largely occurring without specific company news [1][2][3][4] - Acumen Pharmaceuticals, Inc. (ABOS) rose by 8.09% to close at $2.94, adding $0.22 to its share price [1] - Fulgent Genetics, Inc. (FLGT) increased by 5.98% to $28.90, gaining $1.63 in extended trading [1] - Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23, up $0.11 after hours [1] - Coeptis Therapeutics Holdings, Inc. (COEP) finished up 4.14% at $13.85, a gain of $0.55 [2] - Jin Medical International Ltd. (ZJYL) saw an increase of 4.04% to $0.16, up $0.0061 [2] - Alignment Healthcare, Inc. (ALHC) gained 5.92% to $22.20, adding $1.24 in after-hours trading [2] - Orthofix Medical Inc. (OFIX) rose 4.58% to $13.94, up $0.61 [3] - Alto Neuroscience, Inc. (ANRO) advanced 4.52% to $17.57, gaining $0.76 [3] - Immix Biopharma, Inc. (IMMX) increased by 3.87% to $6.17, adding $0.23 [3] - Amneal Pharmaceuticals, Inc. (AMRX) rose 3.76% to $14.35, up $0.52, and is set to replace TTM Technologies in the S&P SmallCap 600 index [3] - Tyra Biosciences, Inc. (TYRA) gained 3.76% to $32.58, adding $1.18 in extended trading [4]

Group 1 - Ero Copper Corp. (ERO) has seen a Zacks Consensus Estimate for its current year earnings increase by 8.1% over the last 60 days [1] - Nu Holdings Ltd. (NU) has experienced a Zacks Consensus Estimate for its current year earnings rise of 7.1% over the last 60 days [1] Group 2 - Kohl's Corporation (KSS) has reported a Zacks Consensus Estimate for its current year earnings increasing by 104.4% over the last 60 days [2] - Fulgent Genetics, Inc. (FLGT) has seen a significant increase in the Zacks Consensus Estimate for its current year earnings by 775% over the last 60 days [2] - The Beachbody Company, Inc. (BODI) has experienced a Zacks Consensus Estimate for its current year earnings increase of 58.3% over the last 60 days [2]

Core Insights - The U.S. anatomic pathology market is projected to reach an estimated revenue of $37.1 billion in 2025, with a long-term annual growth rate of 10.1% driven primarily by increased molecular oncology testing, particularly minimal residual disease (MRD) testing for cancer treatment [3][4]. Market Trends - The report highlights significant changes in the U.S. anatomic pathology market, including the introduction of artificial intelligence tools that enhance pathologist productivity and increased utilization management by private payers, alongside ongoing reimbursement pressures [4][5]. - New higher-priced molecular oncology tests, such as next-generation sequencing for tumor mutation profiling and MRD testing, are expected to counterbalance price and volume pressures on routine pathology tests [5]. Challenges - The primary challenge facing the market comes from third-party payers implementing prior authorization policies and laboratory benefit management programs aimed at reducing the utilization of anatomic pathology services and genetic tests for cancer [6]. Report Features - The report includes over 100 charts and graphs, detailed market size and growth rates, estimates for market subsets like uropathology, dermatopathology, and gastrointestinal pathology, and an in-depth analysis of the molecular oncology testing market [6]. - It also provides Medicare claims data for over 60 key pathology codes, trends in cervical cancer testing, and a detailed analysis of the emerging digital pathology and AI market [6].

Core Insights - Evolent Health reported quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.10 per share, but showing an improvement from $0.04 per share a year ago [1] - The company experienced an earnings surprise of -50.00% and has not surpassed consensus EPS estimates in the last four quarters [2] - Evolent Health's revenues for the quarter were $479.53 million, exceeding the Zacks Consensus Estimate by 2.81%, but down from $621.4 million year-over-year [3] Financial Performance - The earnings report indicates a significant decline in stock performance, with shares down approximately 43.6% year-to-date compared to a 15.6% gain in the S&P 500 [4] - The current consensus EPS estimate for the upcoming quarter is $0.11 on revenues of $471.15 million, and for the current fiscal year, it is $0.18 on revenues of $1.87 billion [8] Industry Context - Evolent Health operates within the Zacks Medical Info Systems industry, which is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable industry outlook [9] - The company has a Zacks Rank of 4 (Sell), indicating expectations of underperformance in the near future based on unfavorable estimate revisions [7]

Company Overview - Schrodinger, Inc. (SDGR) shares increased by 13.8% to close at $21.98, with trading volume significantly higher than usual, contrasting with a 0.7% loss over the past four weeks [1] - The company is expected to report a quarterly loss of $0.72 per share, reflecting a year-over-year decline of 38.5%, while revenues are projected to be $52.68 million, marking a 49.3% increase from the previous year [3] Financial Performance - In the last reported quarter, Schrodinger experienced a 16% year-over-year growth in revenue, driven by increased software and drug discovery revenue [2] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] Market Position - Schrodinger holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook in the market [4] - The company is part of the Zacks Medical Info Systems industry, which includes Fulgent Genetics, Inc. (FLGT), another stock in the same sector that closed 5.1% higher at $23.84 [4]

Core Insights - The genetic screening testing market for preventive health is experiencing rapid growth due to technological advancements, increased consumer interest in personalized medicine, and a rise in preventive healthcare strategies [2][3][5]. Market Overview - The market is driven by improvements in genetic testing technologies, such as next-generation sequencing (NGS), which have made tests more accessible, cost-effective, and accurate [3][5]. - Growing consumer awareness of early detection benefits, rising healthcare costs, and a focus on prevention are fueling demand [3][6]. Market Dynamics - The increasing availability of direct-to-consumer genetic tests empowers individuals to manage their health and gain insights into genetic predispositions [4][5]. - Stakeholders include genetic testing companies, healthcare providers, hospitals, diagnostic laboratories, and wellness organizations [4]. Regional Analysis - North America holds the largest market share, driven by technological advancements and high consumer awareness, with the U.S. being a key player [8]. - Europe is characterized by high demand for genetic tests related to cancer and cardiovascular diseases, with significant investments in preventive healthcare [9]. - The Asia-Pacific region is experiencing significant growth due to rising healthcare awareness and investment in healthcare infrastructure, with China and India emerging as key markets [10]. - The Middle East and Africa show emerging opportunities for genetic screening, particularly in the UAE, Saudi Arabia, and South Africa [11]. Competitive Landscape - Key players in the market include Exact Science, Labcorp Genetics Inc., Blueprint Genetics, Ambry Genetics, and others [7]. - The competitive landscape is marked by strategies such as funding activities, mergers and acquisitions, regulatory approvals, and partnerships [18].